Pfizer: $16.6 Billion Q3 Revenue Supports Higher 2026 Guidance As Newer Medicines Grow 32%
· pulse2.com · popularity 16/100 · 0 similar stories today · Genetics, Genomics & Biotech (Science)
Read the original at pulse2.com →
Summary
Pfizer, a global biopharmaceutical company headquartered in New York, reported third-quarter 2026 revenue of approximately $16.6 billion, with strong performance across several newer medicines offsetting declining sales of COVID-19 products. The company also raised its full-year revenue and adjusted earnings guidance, reflecting its financial performance during the first nine months of the year and continued growth across its commercial portfolio. The post Pfizer: $16.6 Billion Q3 Revenue Supports Higher 2026 Guidance As Newer Medicines Grow 32% appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 16.